Regrowth of optic nerve cells achieved

Article

It may be possible to regenerate optic neural axons by manipulating growth control pathways, according to study results published in the 7 November issue of the journal Science.

It may be possible to regenerate optic neural axons by manipulating growth control pathways, according to study results published in the 7 November issue of the journal Science.

Zhigang He, PhD, BM of the Children's Hospital, Boston, US and colleagues removed a single regulator from retinal ganglion cells (RGCs) of wild-type adult mice in vivo. The receptor, phosphatase and tensin homolog (PTEN), is implicated in the mammalian target of rapamycin (mTOR) pathway.

The team found that removing PTEN was associated with inhibition of mTOR activity and protein synthesis, which prevented axon regeneration. When the mTOR pathway was reactivated by a different regulator, axon regeneration was resumed.

The researchers therefore concluded that modulating growth control pathways could potentially encourage axon regeneration, offering a possible therapeutic solution to optic nerve damage.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.